Adverse effects: Psychopathology ‐ various scales · patients with sexual dysfunction due to antipsychotic drug therapy
1 finding from 1 review
Adverse effects: Extrapyramidal symptoms (Simpson‐Angus) · patients with sexual dysfunction due to antipsychotic drug therapy
1 finding from 1 review
Leaving the study early · patients with sexual dysfunction due to antipsychotic drug therapy
It is very uncertain whether ADJUNCTIVE TREATMENT ‐ SPECIFIC: SILDENAFIL changes leaving the study early compared with PLACEBO (very low certainty).
1 finding from 1 review
Quality of life not reported · patients with sexual dysfunction due to antipsychotic drug therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: Death Not reported · patients with sexual dysfunction due to antipsychotic drug therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: Psychotic symptoms Not reported · patients with sexual dysfunction due to antipsychotic drug therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effect: extrapyramidal symptoms ‐ not reported · patients with sexual dysfunction due to antipsychotic drug therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Effect on later sexual function · patients with sexual dysfunction due to antipsychotic drug therapy
1 finding from 1 review
Leaving the study early · patients with sexual dysfunction due to antipsychotic drug therapy
1 finding from 1 review
Clinically important change in positive symptoms · schizophrenia spectrum disorders with catatonic symptoms
1 finding from 1 review
Clinically important change in negative symptoms · schizophrenia spectrum disorders with catatonic symptoms
1 finding from 1 review
Catatonia: clinically important change in catatonia symptoms (improved at least 50% on the VAS) · schizophrenia spectrum disorders with catatonic symptoms
1 finding from 1 review
Clinically important adverse drug‐induced movement disorder effects on the central nervous system (EPS, NMS, MC) · schizophrenia spectrum disorders with catatonic symptoms
1 finding from 1 review
Clinically important adverse effects other than central nervous system or EPS · schizophrenia spectrum disorders with catatonic symptoms
1 finding from 1 review
Global state: Average endpoint score CGAS (high score = good) · Adolescents with psychosis
1 finding from 1 review
Mental State: Mean end point score PANSS ‐ (high score = good) · Adolescents with psychosis
1 finding from 1 review
Cognitive functioning: Attaining normal cognitive functioning ‐ Not reported · Adolescents with psychosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global functioning: Not reported · Adolescents with psychosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: Not reported · Adolescents with psychosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Service use: Number of participants needing admission · Adolescents with psychosis
PSYCHOEDUCATIONAL (PE) + MULTIFAMILY TREATMENT (MFT) showed no clear difference in service use: Number of participants needing admission compared with NONSTRUCTURED GROUP THERAPY (NSGT, all long‐term) (low certainty).
1 finding from 1 review